7053 Background: Pemetrexed and gemcitabine are synergistic in preclinical models. Each
agent is active in MPM, but the combination has not been studied in this disease in the …

Malignant pleural mesothelioma (MPM) is an aggressive disease with a poor prognosis. The
optimal treatment of MPM was not clearly defined, until the publication of the multicentre …

7093 Background: Aim of this study was to evaluate the activity and toxicity of MTA and
CBDCA combination as first line chemotherapy in advanced MPM. Methods: Chemonaive …

Introduction Malignant pleural mesothelioma (MPM) tumors express vascular epithelial
growth factor (VEGF) and VEGF receptors. We conducted a phase II study of the oral pan …

Background Nintedanib targets VEGF receptors 1–3, PDGF receptors α and β, FGF
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …

Introduction Malignant pleural mesothelioma (MPM) is an aggressive malignancy that most
often presents at an advanced, incurable stage. After the failure of standard first-line …

LBA8505 Background: The vast majority of pts with PM have unresectable disease, due to
co-morbidities and/or advanced stage. In unresectable PM, standard first line treatment has …

Aim: To assess real-world treatment patterns and outcomes among patients with advanced
malignant pleural mesothelioma. Patients & methods: Retrospective database analysis …

Mesothelioma is a rare malignancy of the pleura with limited therapeutic options. Despite the
desperate need to develop better treatment for this disease, the rarity of the tumor type …

Malignant pleural mesothelioma (MPM) is a bad-prognosis cancer raising difficult issues
according to diagnosis. Reliable histological diagnosis indeed requires large-sized …